Institute for Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King’s College London, and the ongoing support of the Wellcome Trust and EPSRC toward the Medical Engineering Centre within King’s College London.

S Bhattacharyya1, Z Atakan1, R Martin-Santos2, JA Crippa3, J Kambeitz1, D Prata1, S Williams4, M Brammer4, DA Collier3 and PK McGuire1

1Department of Psychosis Studies, King’s College London, Institute of Psychiatry, De Crespigny Park, London, UK; 2Pharmacology Research Unit, IMIM-Hospital del Mar and Psychiatric Department, ICN, Hospital Clinic, IDIBAPS, CIBERSAM, Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain;

3Department of Neurology, Psychiatry and Medical Psychology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil; 4Department of Neuroimaging, Centre for Neuroimaging Sciences, PO Box 089, King’s College London, Institute of Psychiatry, De Crespigny Park, London, UK and 5Social, Genetic & Developmental Psychiatry Centre, PO Box 082, King’s College London, Institute of Psychiatry, De Crespigny Park, London, UK

E-mail: sagnik.2.bhattacharyya@kcl.ac.uk

References

1 Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C et al. Arch Gen Psychiatry 2009; 66: 442–451.

2 Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Neuropsychopharmacology 2009; 34: 759–766.

3 Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Nat Rev Neurosci 2007; 8: 885–895.

4 Stokes PR, Egerton A, Watson B, Reid A, Breen G, Lingford-Hughes A et al. Neuroimage 2010; 52: 1521–1527.

5 Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Neuroimage 2009; 48: 186–190.

6 Murray RM, Morrison PD, Henquet C, Di Forti M. Nat Rev Neurosci 2007; 8: 883–895.

7 Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Proc Natl Acad Sci USA 2009; 106: 617–622.

8 Beaulieu JM, Gainetdinov RR, Caron MG. Trends Pharmacol Sci 2007; 28: 166–172.

9 Prata DP, Mechelli A, Picchioni MM, Fu CH, Toulouropoulou T, Bramon E et al. Arch Gen Psychiatry 2009; 66: 1162–1172.

10 Heinz A, Goldman D, Jones DW, Palmour S, Hommer D, Gorey JG et al. Neuropsychopharmacology 2000; 22: 133–139.

11 van Winkel R. Arch Gen Psychiatry 2011; 68: 148–157.

12 Talkowski ME, Kirav G, Banne M, Georgieva L, Torres G, Mansour H et al. Hum Mol Genet 2008; 17: 747–758.

13 Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R et al. J Clin Invest 2008; 118: 2200–2208.

14 Emanuel ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Nat Genet 2004; 36: 131–137.

15 Ozaita A, Puigserver E, Maldonado R. J Neurochem 2007; 102: 1105–1114.

16 Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al. Biol Psychiatry 2005; 57: 1117–1127.

17 Henquet C, Rosa A, Delespaul P, Papilo S, Fananas L, van Os J et al. Acta Psychiatr Scand 2009; 119: 156–160.

Letters to the Editor

Open

Schizophrenia risk gene ZNF804A does not influence macroscopic brain structure: an MRI study in 892 volunteers

Molecular Psychiatry (2012) 17, 1155–1157; doi:10.1038/mp.2011.181; published online 24 January 2012

The single nucleotide polymorphism (SNP) rs1344706 in the ZNF804A gene was the first SNP to reach unequivocal genome-wide significance for schizophrenia, but little is known about how it confers susceptibility. Here, we looked for neuroanatomical correlates of rs1344706, and of other SNPs across the gene, in a large structural MRI data set of healthy young adults, using brain volumetry and voxel-based morphometry (VBM). Neither rs1344706 nor the other SNPs, individually or in combination, affected any volumetric or VBM parameter. As such, the association of ZNF804A with psychosis seems unlikely to be mediated through an influence of rs1344706 or any other SNP on macroscopic brain structure.

Schizophrenia and bipolar disorder are highly heritable disorders. Data from genome-wide association studies (GWAS) provide compelling evidence for association to the ZNF804A (zinc finger protein 804A) gene, at chromosome 2q32.1. Association to schizophrenia was originally reported in 2008, and a recent meta-analysis of > 21 000 cases and 38 000 controls found an odds ratio (OR) of 1.10, P = 4 × 10⁻¹³ for schizophrenia, and OR 1.11, P = 2.5 × 10⁻¹¹ for schizophrenia and bipolar disorder combined. The genetic signal arises predominantly from a single, intragenic SNP, rs1344706 or possibly a haplotype that includes it. The roles of ZNF804A and the functional correlates of rs1344706 are unclear, although the latter is predicted to create a transcription factor-binding site and to affect gene expression of ZNF804A.

Several studies have used neuroimaging to examine whether rs1344706 impacts upon brain structure. Lenz et al. showed in 39 healthy volunteers that carriers of the risk allele (A) of rs1344706 had significantly larger total white matter but reduced gray matter volume compared with carriers of the wild-type allele (G).

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)
matter volumes in several regions comprising the ‘default mode network’. Other studies reported that the risk allele affected volumes of the amygdala and hippocampus in 70 patients but not in 38 healthy controls,6 and cortical thickness was reduced in the anterior cingulate, posterior cingulate and superior temporal gyrus in 62 healthy volunteers, with no changes in white matter tracts.7 A Chinese study found decreased white matter density in the left prefrontal lobe of 69 healthy risk allele carriers. 8 However, all these studies were limited in terms of their sample sizes and no ZNF804A SNPs other than rs1344706 were examined.

Here, we studied the effects of ZNF804A on brain structure in a sample of 892 healthy young adults participating in the Brain Imaging Genetics (BIG) study (see Supplementary Table 1). Of these, 422 volunteers were scanned at 1.5 Tesla (T) and 470 at 3T. We implemented two analysis methods—volumetry and VBM—to look at the effects of rs1344706, and the individual and combined effects of 266 other SNPs in ZNF804A. The genetic data were available from an Affymetrix Genome-Wide Human SNP Array 6.0 and a subsequent imputation step using HapMap2 as reference sample (CEU data, NCBI build 36, UCSC hg18, http://www.sph.umich.edu/csg/abecasis/MaCH/download/). The gene-wide analysis method used a statistical approach as described by Hoh et al.10 where the analysis consisted of a SNP-by-SNP linear regression and the estimation of the effect of the complete gene on the volumes. The single SNP and gene-wide effects were assessed for gray matter, white matter and total brain volume, as well as eight circumscribed brain structures: nucleus accumbens, amygdala, brainstem, caudate nucleus, globus pallidus, hippocampus, putamen and thalamus. With VBM, we looked for genetic effects on regional differences across the whole brain in both the 1.5T and the 3T groups using a full-factorial ANCOVA with age, sex, scan protocol and total brain volume as covariates. To increase statistical sensitivity, we applied small volume corrections for regions of interest (dorsolateral prefrontal cortex, hippocampus, amygdala, anterior cingulate cortex and posterior cingulate cortex). See Supplementary Methods for details of imaging methods and genetic analysis.

The volumetry results for rs1344706 are presented in Table 1. They reveal no effects on either total brain volume, gray or white matter, or the regions of interest measured (all \( P > 0.05 \)).

Similarly, VBM revealed no effects of rs1344706, either in the whole-brain analysis or in any of the regions of interest (Supplementary Table 2). Results for the gene-wide approach were also negative (Supplementary Tables 3–5). We also compared rs1344706 AA homozygotes versus CC homozygotes; again, there was no influence on any brain measure analysed (data not shown).

In summary, we have shown that genetic variation in ZNF804A, including the genome-wide significant psychosis risk allele rs1344706, does not affect total or regional brain volumes in healthy young adults. Compared with previous reports, we studied a far larger sample, used both volumetry and VBM and also conducted a gene-wide approach. The method has been shown previously to be effective for the detection of genetic effects on MRI volumes in the BIG database.9 Together, our results strongly suggest that rs1344706 in particular, and sequence variation in ZNF804A in general, do not impact upon macroscopic brain structure. While we cannot rule out such effects occurring in childhood or in clinical populations, it is more likely that any pathophysiological correlates of genetic variation in ZNF804A occur via modulation of brain function or connectivity.

**Conflict of interest**

The authors declare no conflict of interest.

| Table 1  | Brain volumes according to rs1344706 genotype |
|----------|---------------------------------------------|
| Genotype | C/C | C/A | A/A | P-value |
| N        | 160 | 434 | 297 |        |
| Frequency| 0.18| 0.49| 0.33|        |
| Accumbens| 0.67(0.12)| 0.69 (0.12)| 0.68 (0.11)| 0.86 |
| Amygdala | 2.15 (0.39) | 2.14 (0.36) | 2.14 (0.37) | 0.52 |
| Brainstem| 19.23 (2.32) | 19.39 (2.32) | 19.22 (2.33) | 0.37 |
| Caudate nucleus | 5.45 (0.66) | 5.52 (0.61) | 5.52 (0.58) | 0.45 |
| Gray matter | 829.9 (79.57) | 838.0 (71.49) | 838.0 (77.80) | 0.27 |
| Globus pallidus | 1.88 (0.23) | 1.89 (0.21) | 1.89 (0.21) | 0.84 |
| Hippocampus | 5.33 (0.68) | 5.37 (0.64) | 5.31 (0.63) | 0.35 |
| Putamen | 6.21 (0.70) | 6.24 (0.69) | 6.23 (0.72) | 0.82 |
| Total brain volume | 1304 (129.1) | 1317 (113.4) | 1314 (120.1) | 0.70 |
| Thalamus | 11.43 (1.20) | 11.55 (1.08) | 11.44 (1.12) | 0.32 |
| White matter | 474.1 (56.74) | 479.5 (51.22) | 476.2 (51.81) | 0.56 |

Values are mm³, mean (s.d.). Genotype data missing for one subject.
Oxytocin receptor (OXTR) is not associated with optimism in the Nurses’ Health Study

Molecular Psychiatry (2012) 17, 1157–1159; doi:10.1038/mp.2011.178; published online 3 January 2012

The oxytocin system is implicated in complex social behavior such as socioemotional functioning, social recognition and bonding, and in modulating biological responses to stress. The oxytocin receptor (OXTR) gene encodes the OXTR, a G-protein-coupled receptor that mediates the effects of the neurohormone oxytocin. Prior studies have reported associations between an intronic single-nucleotide polymorphism (rs53576) of OXTR and various stress-related and psychological traits. Most recently, Saphire-Bernstein et al. reported that rs53576 A allele carriage conferred lower optimism relative to G homozygotes, among 344 men and women aged 18–36 years of various ethnicities. We sought to replicate the association between OXTR rs53576 and optimism in 1229 women from the Nurses’ Health Study (NHS).

The NHS was established in 1976 when 121,700 women registered as nurses aged 30–55 years from 11 US states completed a mailed questionnaire on medical history and lifestyle characteristics. Every 2 years, follow-up questionnaires are sent. The 2004 and 2008 questionnaires included information on antidepressant use and the revised life orientation test, the same dispositional optimism measure used in the Saphire-Bernstein et al. study. We generated five different optimism scores to provide a thorough investigation of the previously reported association. Year-specific optimism scores were derived by taking the mean of all non-missing items in 2004 (T=0.77) and also in 2008 (T=0.75). Individuals with >2 items missing were excluded (up to 8% of analytic sample). Using both assessments, an overall mean optimism score was also derived, as were two subscale scores reflecting an ‘optimistic’ or ‘pessimistic’ outlook. Genotypes for the current analysis were available from two case-control nested genome-wide association studies, initially designed to assess kidney stone disease and glaucoma (total n=1294). Samples were genotyped for OXTR rs53576 at the Broad Center for Genotyping and Analysis using the Illumina 610Q or 660Q array (Illumina, San Diego, CA, USA). Genotyping success rate for rs53576 was >98%. Principal components analyses using genome-wide data were conducted to assess self-reported race. Genetically inferred non-Caucasian samples were too few (<3% of analytic sample) for meaningful analysis and therefore excluded.

The 2004 and 2008 optimism scores were moderately correlated (r=0.65) in the 1229 women with complete genetic and phenotype data (2004 mean age=71.3 years, s.d.=6.7). Overall optimism scores ranged from 1.33 to 4.25 (overall mean=4.13, s.d.=0.68). Frequencies (%) of the GG, GA and AA genotypes were 491 (40%), 559 (45%) and 179 (15%), respectively, and did not depart from Hardy–Weinberg equilibrium (P=0.33). The A allele frequency was 38% in NHS versus 28% among white participants (n=87) in the Saphire-Bernstein et al. study.

Table 1 indicates no significant differences in means across genotypes for any optimism scores (all PADD >0.35). Optimism scores also did not differ between G homozygotes and A carriers (all PDOM >0.17). Linear regression models adjusting for age, genotype platform, and case-control status yielded no significant association between rs53576 and any optimism score, regardless of genetic model (all

References
1 O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V et al. Nat Genet 2008; 40: 1053–1055.
2 Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L et al. Mol Psychiatry 2011; 16: 429–441.
3 Riley B, Thiselton D, Maher BS, Bigdeli T, Wormley B, McMichael GO et al. Mol Psychiatry 2010; 15: 29–37.
4 Hill MJ, Bray NJ. Mol Psychiatry 2011; 16: 787–789.
5 Lenz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM et al. Neuropsychopharmacology 2010; 35: 2284–2291.
6 Donohoe G, Rose E, Froud T, Morris D, Spalletini I, Adriano F et al. NeuroImage 2011; 54: 2132–2137.
7 Voineskos AN, Lerch JP, Folsky D, Tiwari A, Rajji TK, Miranda D et al. Neuropsychopharmacology 2011; 36: 1871–1878.
8 Wei Q, Kang Z, Diao F, Shan B, Li L, Zheng L et al. Neuropsychopharmacol Biol Psychiatry 2011; 36: 122–127.
9 Braalten J, Arias-Vasquez A, Makkinje R, Veltman JA, Brunner HG, Fernandez G et al. Am J Psychiatry 2011; 168: 1083–1089.
10 Hoh J, Wille A, Ott J. Genome Res 2011; 21: 1157–1159; doi:10.1101/gr.140188.110.